Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Quick facts
Marketed products
- Empirical antimicrobial treatment discontinuation
- Fludeoxyglucose 18F · Metabolic
- PEG-3350 with electrolytes
- Polyethylene Glycol 4000 with electrolytes · Gastroenterology
Polyethylene glycol 4000 with electrolytes acts as an osmotic laxative that draws water into the bowel lumen while the electrolytes maintain fluid and electrolyte balance. - Standard empirical antimicrobial treatment discontinuation · Infectious Disease / Antimicrobial Stewardship
This is a clinical protocol for discontinuing empirical broad-spectrum antimicrobial therapy based on standardized criteria rather than a pharmacological drug.
Phase 3 pipeline
- Antipseudomonal beta-lactam antibiotic · Infectious Disease
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell wall rupture and bacterial death, with activity against Pseudomonas aeruginosa and other gram-negative organisms. - Ceftriaxone intravenous · Infectious Disease
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking cross-linking of peptidoglycan. - Fosfomycin sodium intravenous · Infectious Disease
Fosfomycin inhibits bacterial cell wall synthesis by inactivating the MurA enzyme, preventing peptidoglycan cross-linking. - Meropenem intravenous · Infectious Disease
Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. - romiplostim plus dexamethasone · Hematology/Immunology
Romiplostim stimulates thrombopoietin receptors to increase platelet production, while dexamethasone provides immunosuppressive and anti-inflammatory effects to treat immune thrombocytopenia.
Phase 2 pipeline
- haloperidol, pimozide, olanzapine, risperidone, amisulpride
- High doses of Thiamine y Biotin
- Maraviroc experimental group
- Moderate doses of Thiamine y Biotin
- No antiplatelet treatment
- Regulatory T-cell enriched infusion
- Usual Antipsychotic Treatment
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla portfolio CI brief
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla pipeline updates RSS
Frequently asked questions about Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
What are Fundación Pública Andaluza para la gestión de la Investigación en Sevilla's marketed drugs?
Top marketed products include Empirical antimicrobial treatment discontinuation, Fludeoxyglucose 18F, PEG-3350 with electrolytes, Polyethylene Glycol 4000 with electrolytes, Standard empirical antimicrobial treatment discontinuation.
What is Fundación Pública Andaluza para la gestión de la Investigación en Sevilla's pipeline?
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla has 5 drugs in Phase 3, 7 in Phase 2, 1 in Phase 1. Late-stage candidates include Antipseudomonal beta-lactam antibiotic, Ceftriaxone intravenous, Fosfomycin sodium intravenous, Meropenem intravenous.
Related
- Empirical antimicrobial treatment discontinuation
- Fludeoxyglucose 18F · Metabolic
- PEG-3350 with electrolytes
- Polyethylene Glycol 4000 with electrolytes · Gastroenterology
- Standard empirical antimicrobial treatment discontinuation · Infectious Disease / Antimicrobial Stewardship
- Sector hub: All tracked pharma companies